Rexford Industrial Realty Inc
Change company Symbol lookup
Select an option...
REXR-A Rexford Industrial Realty Inc
DPW DPW Holdings Inc
IWN iShares Russell 2000 Value ETF
XNXCX Nuveen California Select Tax-Free Income Portfolio
AMGN Amgen Inc
AMSC American Superconductor Corp
CVBF CVB Financial Corp
PHG Koninklijke Philips NV
IVR Invesco Mortgage Capital Inc
CORE Core-Mark Holding Company Inc
Go

Real Estate : Equity Real Estate Investment Trusts (REITs) | Small Cap Growth
Company profile

Rexford Industrial Realty, Inc. is a self-administered and self-managed real estate investment trust (REIT). The Company is focused on owning and operating industrial properties in Southern California infill markets. Through its controlling interest in its Rexford Industrial Realty, L.P. (Operating Partnership) and its subsidiaries, it owns, manages, leases, acquires and develops industrial real estate principally located in Southern California infill markets, and, from time to time, acquire or provide mortgage debt secured by industrial property. It owns a portfolio of approximately 236 properties with approximately 29.9 million rentable square feet. In addition, it manages approximately 20 properties with approximately one million rentable square feet.

This security is a preferred stock
Closing Price
$25.22
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
19,621
0

The Law Offices of Frank R. Cruz Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors

12:30 pm ET November 19, 2020 (BusinessWire) Print

The Law Offices of Frank R. Cruz announces an investigation of Biogen, Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) on behalf of investors concerning the Company's possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 22, 2019, the Company announced that it would seek regulatory approval from the U.S. Food and Drug Administration ("FDA") for aducanumab "based on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 clinical studies that were discontinued in March 2019 following a futility analysis." According to Biogen, the new analysis "show[ed] that aducanumab is pharmacologically and clinically active as determined by dose-dependent effects in reducing brain amyloid and in reducing clinical decline as assessed by the pre-specified primary endpoint Clinical Dementia Rating-Sum of Boxes (CDR-SB)."

On November 6, 2020, Reuters reported that an FDA panel found it "cannot ignore unsuccessful trial data on Biogen Alzheimer's drug." The panel had also "voted that an earlier-stage study does not offer supportive evidence of Biogen's application for the drug, aducanumab."

On this news, the Company's stock price fell $92.64 per share, or 28%, to close at $236.26 per share on November 9, 2020, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Biogen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005646/en/

SOURCE: The Law Offices of Frank R. Cruz">

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com 
www.frankcruzlaw.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.